Document
IPR2023-00724, No. 2518 Exhibit - EX2518 Han, SH, et al, Public Interest in the Off Label Use of Glucagon like Peptide 1 Agonists Ozempic for Cosmetic Weight Loss A Google Trends Analysis...
Cite Document
IPR2023-00724, No. 2518 Exhibit - EX2518 Han, SH, et al, Public Interest in the Off Label Use of Glucagon like Peptide 1 Agonists Ozempic for Cosmetic Weight Loss A Google Trends Analysis, Aesthetic
+ More Snippets
Document
IPR2023-00724, No. 2410 Exhibit - EX2410 Novo Nordisk, “Dosing and administering Victoza®,” httpswwwnovomedlinkcomdiabetesproductstreatmentsvictoza dosing administrationhtml (P.T.A....
Cite Document
IPR2023-00724, No. 2410 Exhibit - EX2410 Novo Nordisk, “Dosing and administering Victoza®,” httpswwwnovomedlinkcomdiabetesproductstreatmentsvictoza dosing administrationhtml (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2357 Exhibit - EX2357 National Institute of Diabetes and Digestive Kidney Diseases, “Type 2 Diabetes,” httpswwwniddknihgovhealth informationdiabetesoverviewwhat is dia...
Cite Document
IPR2023-00724, No. 2357 Exhibit - EX2357 National Institute of Diabetes and Digestive Kidney Diseases, “Type 2 Diabetes,” httpswwwniddknihgovhealth informationdiabetesoverviewwhat is diabetestype 2
+ More Snippets
Document
IPR2023-00724, No. 1092 Exhibit - Anstaett Declaration (P.T.A.B. Dec. 18, 2023)
Cite Document
IPR2023-00724, No. 1092 Exhibit - Anstaett Declaration (P.T.A.B. Dec. 18, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1117 Exhibit - Exhibit 1117 Disapproval (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1117 Exhibit - Exhibit 1117 Disapproval (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2377 Exhibit - EX2377 Janssen Pharmaceuticals, Inc, “US FDA Approves INVOKANA™ Canagliflozin for the Treatment of Adults with Type 2 Diabetes,” httpswwwprnewswire...
Cite Document
IPR2023-00724, No. 2377 Exhibit - EX2377 Janssen Pharmaceuticals, Inc, “US FDA Approves INVOKANA™ Canagliflozin for the Treatment of Adults with Type 2 Diabetes,” httpswwwprnewswirecomnews releasesu
+ More Snippets
Document
IPR2023-00724, No. 2482 Exhibit - EX2482 Novo Nordisk, Possible Side Effects of Ozempic semaglutide Injection, httpswwwozempiccomhow to takeside effectshtml (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2482 Exhibit - EX2482 Novo Nordisk, Possible Side Effects of Ozempic semaglutide Injection, httpswwwozempiccomhow to takeside effectshtml (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2010 Exhibit - EX2010 Expert Declaration of Julio Rosenstock, MD (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2010 Exhibit - EX2010 Expert Declaration of Julio Rosenstock, MD (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1304 Exhibit - Exhibit 1304 Schwartzbard Decl (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1304 Exhibit - Exhibit 1304 Schwartzbard Decl (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2001 Exhibit - EX2001 US Patent No 9,764,003 File History (P.T.A.B. Jul. 6, 2023)
Cite Document
IPR2023-00724, No. 2001 Exhibit - EX2001 US Patent No 9,764,003 File History (P.T.A.B. Jul. 6, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1083 Exhibit - Transfer order (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1083 Exhibit - Transfer order (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1016 Exhibit - US20070010424 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1016 Exhibit - US20070010424 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1027 Exhibit - Holst 1987 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1027 Exhibit - Holst 1987 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 2553 Exhibit - EX2553 Transcript of July 12, 2024 Deposition of William J Jusko, PhD (P.T.A.B. Jul. 31, 2024)
Cite Document
IPR2023-00724, No. 2553 Exhibit - EX2553 Transcript of July 12, 2024 Deposition of William J Jusko, PhD (P.T.A.B. Jul. 31, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2656 Exhibit - EX2656 July 12, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft ...
Cite Document
IPR2023-00724, No. 2656 Exhibit - EX2656 July 12, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft proposed motion
+ More Snippets